CRVS241220C18000
- 0.25
- 0.000.00%
Corvus Pharmaceuticals Newsroom
A Quick Look at Today's Ratings for Corvus Pharmaceuticals(CRVS.US), With a Forecast Between $13 to $24
Corvus Pharma Analyst Ratings
Corvus Stock Climbs 7% Following Mizuho Upgrade
Mizuho Securities Upgrades Corvus Pharmaceuticals(CRVS.US) to Buy Rating, Announces Target Price $12
Corvus Pharma Analyst Ratings
Ladenburg Thalmann Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Raises Target Price to $21
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Corvus Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Adaptimmune Therapeutics (ADAP) and Corvus Pharmaceuticals (CRVS)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Editas Medicine (EDIT), Corvus Pharmaceuticals (CRVS) and AC Immune SA (ACIU)
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI), Arcutis Biotherapeutics (ARQT) and Corvus Pharmaceuticals (CRVS)
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Cantor Fitzgerald Reiterates Overweight on Corvus Pharma, Maintains $4 Price Target
Corvus Pharma Analyst Ratings
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target
The Latest Analyst Ratings for Corvus Pharma